Physician profile
Xinting Fu
NPI 1770650582
$6,180.47
in general payments reported to CMS, 2019-2025
21 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $182 · 2021: $1,262 · 2022: $1,424 · 2023: $2,201 · 2024: $71.79 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,400 · Food and Beverage: $966 · Consulting Fee: $175 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,400.00 |
| Food and Beverage | $965.67 |
| Consulting Fee | $175.00 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $1,615.19 | 2023 | Firdapse |
| E.R. Squibb & Sons, L.L.C. | $1,414.98 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $694.76 | 2020-2025 | Ultomiris |
| Astellas Pharma US INC | $548.48 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $370.32 | 2019-2021 | |
| Amgen INC. | $274.36 | 2019-2021 | |
| Immunocore Limited | $164.33 | 2024-2025 | Kimmtrak |
| Tg Therapeutics, INC. | $149.14 | 2022 | |
| Abbvie INC. | $141.06 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $126.53 | 2021 | |
| Servier Pharmaceuticals LLC | $124.99 | 2021 | |
| Emd Serono, INC. | $120.40 | 2023 | Bavencio |
| Eisai INC. | $119.18 | 2022 | |
| Incyte Corporation | $117.61 | 2022 | |
| Blueprint Medicines Corporation | $46.48 | 2023 | Ayvakit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.36 | 2019 | |
| Celgene Corporation | $27.39 | 2019 | |
| Taiho Oncology, INC. | $19.54 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.53 | 2024 | Pyrukynd |
| Pfizer INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xinting Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.